Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
Population Pharmacokinetics of Anti-infectious Drugs in Children
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 214
- Registration Number
- NCT01344512
- Locations
- 🇫🇷
APHP - Hôpital NEcker, Paris, France
🇫🇷CHU Poitiers, Poitiers, France
🇫🇷CHU de Dijon, Dijon, France
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01188759
Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1002
- Registration Number
- NCT01151085
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01148160
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 61
- Registration Number
- NCT01104376
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 10
- Registration Number
- NCT01101386
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT01092832
- Locations
- 🇵🇭
Medical Research Laboratory Philippine General Hospital University of the Philippines, Ermita,, Manila, Philippines
🇵🇭Rm. 112 ICHHD, National Institutes of Health-University of the Philippines Manila, Manila, Philippines
🇨🇳Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01080651
- Locations
- 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of
Mycotic Ulcer Treatment Trial I
- Conditions
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 323
- Registration Number
- NCT00996736
- Locations
- 🇮🇳
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India
🇮🇳Aravind Eye Hospitals, Madurai, Tamil Nadu, India
🇺🇸Proctor Foundation, UCSF, San Francisco, California, United States
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
- Conditions
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 240
- Registration Number
- NCT00997035
- Locations
- 🇮🇳
Aravind Eye Hospitals, Madurai, Tamil Nadu, India
🇮🇳Aravind Eye Hospital, Tirunelveli, Tamil Nadu, India
🇺🇸Proctor Foundation, UCSF, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.